Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314542 | 0.94 | KDM4E (0.71) | KDM4EALDH1A1POLBRAB9APDE5A | |
| SCHEMBL3314287 | 0.93 | KDM4E (0.74) | KDM4EALDH1A1POLBRAB9ARCE1 | |
| SCHEMBL3319335 | 0.92 | KDM4E (0.70) | KDM4EALDH1A1POLBL3MBTL1KMT2A | |
| SCHEMBL3313199 | 0.92 | KDM4E (0.75) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3318074 | 0.91 | KDM4E (0.69) | KDM4EALDH1A1POLBRAB9AKMT2A | |
| SCHEMBL3312861 | 0.91 | KDM4E (0.69) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3319419 | 0.90 | KDM4E (0.68) | KDM4EALDH1A1POLBPDE5AKMT2A | |
| SCHEMBL3318235 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3314425 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1POLBRAB9AKMT2A | |
| SCHEMBL3310748 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | KDM4E 332/4885ALDH1A1 576/4885POLB 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.